Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01166126 · ClinicalTrials.gov registry record · Phase 2
Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IV
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT01166126: Clinical Trial Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT01166126 is a Phase 2 study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 4 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01166126, a Phase 2 study, was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
The purpose of this study is to find out how often two investigational drugs that are given together will shrink the patient's tumor and how well they will prolong the time it takes their tumor to grow. The investigators also wish to find out how they affect certain substances in the patient's tumor and in their blood important for tumor growth. The combination of these drugs is experimental, and has not been proven to help treat melanoma
Interventions
- OTHER laboratory biomarker analysis
- DRUG selumetinib
- DRUG temsirolimus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2010-10 |
| Est. Completion | 2012-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01166126
The ClinicalTrials.gov registry entry for NCT01166126 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT01166126 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01166126 about?
NCT01166126 is a clinical study titled "Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IV". The purpose of this study is to find out how often two investigational drugs that are given together will shrink the patient's tumor and how well they will prolong the time it takes their tumor to grow. The investigators also wish to find out how they affect certain substances in the patient's tumor...
What is the current status of trial NCT01166126?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2010-10. Estimated completion is 2012-06.
What interventions are being tested in trial NCT01166126?
The interventions under investigation include: laboratory biomarker analysis (OTHER), selumetinib (DRUG), temsirolimus (DRUG).
Who is sponsoring clinical trial NCT01166126?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.